Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lean Beef Consumption and Insulin Sensitivity in Men and Women With Risk Factors for Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03202680
Recruitment Status : Completed
First Posted : June 28, 2017
Last Update Posted : July 24, 2019
Sponsor:
Collaborator:
National Cattlemen's Beef Association
Information provided by (Responsible Party):
Midwest Center for Metabolic and Cardiovascular Research

Brief Summary:
The objective of this trial is to compare the effects of a healthy, lean beef diet and an average American, United States Department of Agriculture (USDA) style diet, that is low in saturated fatty acids (SFA), on insulin sensitivity in men and women with risk factors for diabetes mellitus.

Condition or disease Intervention/treatment Phase
Metabolic Syndrome PreDiabetes Other: USDA Style Diet Other: Lean Beef Diet Not Applicable

Detailed Description:

This is a randomized, controlled, crossover study that includes two screening visits, one baseline visit, two 28-d test periods and an end-of-washout visit. A 2-week washout period will separate the two treatments. Subjects will be screened to identify metabolic syndrome and/or prediabetes at the screening visits. Eligible subjects will be randomly assigned to a test sequence (USDA/lean beef or lean beef/USDA diets) and the appropriate calorie menu within each test diet, which will be determined based on each subject's calculated energy needs for weight maintenance. Study foods will be dispensed, and subjects will be instructed to consume all of the foods in their entirety for the duration of each 28-d test period, and avoid consuming any additional food or drink items that has not been provided to them. Compliance will be assessed through a Food Deviation Log where subjects will record any non-study food/beverages consumed, and any portions of the study foods not consumed.

An intravenous glucose tolerance test (IVGTT) will be completed at baseline and the end of each treatment period, and fasting glucose and insulin will also be measured at screening and at the first test visit in each treatment period. Fasting blood samples will be collected for lipid profile and high-sensitivity C-reactive protein (hs-CRP) measurements at all treatment visits. Additionally, fasting blood will be drawn for measurement of apolipoprotein B and A1 and lipoprotein particles and subfractions at baseline and the end of each treatment period.

Assessments of vital signs, body weight, evaluation of inclusion and exclusion criteria, medication/supplement use, and adverse effects will be performed throughout the study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: A Randomized, Controlled-Feeding, Crossover Trial to Assess the Effects of Increasing Lean Beef Consumption Within a Healthy Dietary Pattern on Insulin Sensitivity in Men and Women With Risk Factors for Diabetes Mellitus.
Actual Study Start Date : July 6, 2017
Actual Primary Completion Date : July 16, 2018
Actual Study Completion Date : July 16, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy

Arm Intervention/treatment
Active Comparator: USDA Style Diet
Healthy, low saturated fat, United States Department of Agriculture (USDA) style diet.
Other: USDA Style Diet
USDA style healthy diet, low in saturated fats.

Experimental: Lean Beef Diet
Healthy, low saturated fat, high in lean beef diet.
Other: Lean Beef Diet
A lean beef containing healthy diet, low in saturated fats.




Primary Outcome Measures :
  1. Change in insulin sensitivity index (Si) [ Time Frame: Up to 50 minutes - measured at baseline, and end of each treatment period. ]
    Differences in the change from baseline between test conditions (lean beef diet and USDA diet) in the insulin sensitivity index (Si) using the short IVGTT.


Secondary Outcome Measures :
  1. Disposition index of pancreatic beta-cell function [Si x acute insulin response to intravenous glucose (AIRg)] [ Time Frame: Up to 50 minutes - measured at baseline, and end of each treatment period. ]
    Percent change (or change) from baseline to the end of each test condition.

  2. Fractional glucose disappearance constant from t = 10-50 min (Kg) [ Time Frame: Up to 50 minutes - measured at baseline, and end of each treatment period. ]
    Percent change (or change) from baseline to the end of each test condition.

  3. Homeostasis model assessment of beta cell function (HOMA%B) and insulin sensitivity (HOMA%S) [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change (or change) from baseline to the end of each test condition.

  4. Insulin sensitivity (HOMA%S) [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change (or change) from baseline to the end of each test condition.

  5. Total Cholesterol (TC) [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change (or change) in TC from baseline to the end of each test condition

  6. Low-density Lipoprotein Cholesterol (LDL-C) [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change (or change) in LDL-C from baseline to the end of each test condition

  7. High-density Lipoprotein Cholesterol (HDL-C) [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change (or change) in HDL-C from baseline to the end of each test condition

  8. Non-HDL-C [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change (or change) in Non-HDL-C from baseline to the end of each test condition

  9. Triglycerides (TG) [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change (or change) in TG from baseline to the end of each test condition

  10. TC/HDL-C ratio [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change (or change) in TC/HDL-C ratio from baseline to the end of each test condition

  11. High-sensitivity C-reactive protein (hs-CRP) [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change (or change) from baseline to the end of each test condition in levels of hs-CRP

  12. Resting, seated systolic and diastolic blood pressures [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change (or change) from baseline to the end of each test condition.

  13. Lipoprotein subfraction and particle concentrations. [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change (or change) in lipoprotein subfraction and particle concentrations from baseline to the end of each test condition.

  14. Apo B measurements. [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change (or change) in Apo B levels from baseline to the end of each test condition.

  15. Apo A1 measurements. [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change (or change) in Apo A1 levels from baseline to the end of each test condition.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. BMI of 25.0-39.9 kg/m2.
  2. Metabolic syndrome (exhibiting at least 3 out of 5 of the criteria) AND/OR prediabetes (either fingerstick glycated hemoglobin 5.7-6.4%, fasting fingerstick capillary glucose of 100-125 mg/dL, or 2-h post-prandial glucose of 140-199 mg/dL).
  3. Fasting LDL-C level <200 mg/dL and fasting TG level <400 mg/dL.
  4. Willingness to consume only study-related foods/beverages during each test period and consume all of the study foods provided for each day.
  5. Willingness to come to the clinic for study food pick-up as needed.
  6. Judged to be in general good health, aside from the inclusionary metabolic criteria for the study, on the basis of medical history and screening laboratory tests.

Exclusion Criteria:

  1. Atherosclerotic cardiovascular disease including any of the following: clinical signs of atherosclerosis including peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease [symptomatic (e.g., transient ischemic attack or stroke of carotid origin) or >50% stenosis on angiography or ultrasound], history of myocardial infarction, angina, or other forms of clinical atherosclerotic disease (e.g., renal artery disease).
  2. History or presence of clinically important pulmonary (including uncontrolled asthma), endocrine (including type 1 or type 2 diabetes mellitus), chronic inflammatory disease (including irritable bowel disease, lupus, rheumatoid arthritis), hepatic, renal, hematologic, immunologic, dermatologic, neurologic, psychiatric, or biliary disorders.
  3. Known allergy, sensitivity, or intolerance to any ingredients in the study foods (e.g., dairy, nuts, etc.).
  4. Uncontrolled hypertension.
  5. Recent history of cancer except for non-melanoma skin cancer.
  6. Recent change in body weight of ± 4.5 kg (10 lbs).
  7. Unstable use of any antihypertensive medication.
  8. Recent use of medications intended to alter the lipid profile [e.g., bile acid sequestrants, cholesterol absorption inhibitor, fibrates, niacin (drug form), omega-3-ethyl ester drugs, and/or proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors], weight-loss drugs or programs, systemic corticosteroid drugs, medications known to influence carbohydrate metabolism (e.g., adrenergic receptor blockers, diuretics, and/or hypoglycemic medications).
  9. Recent use of foods or dietary supplements known to influence lipid metabolism (e.g., omega-3 fatty acids supplements or fortified foods, sterol/stanol products, red rice yeast supplements, garlic supplements, soy isoflavone supplements, niacin or its analogues at doses >400 mg/d and irregular or inconsistent use of Metamucil® or viscous fiber-containing supplements.
  10. Recent use of antibiotics.
  11. Pregnant, planning to be pregnant during the study period, lactating, or of childbearing potential and unwilling to commit to the use of a medically approved form of contraception throughout the study period.
  12. Extreme dietary habits (e.g., very low carbohydrate diet, vegan, vegetarian, etc.) or unwillingness to consume study foods.
  13. Current or recent history or strong potential for drug or alcohol abuse.
  14. History of a diagnosed eating disorder (e.g., anorexia or bulimia nervosa).
  15. Recent exposure to any non-registered drug product.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03202680


Locations
Layout table for location information
United States, Florida
MB Clinical Research, LLC
Boca Raton, Florida, United States, 33487
Sponsors and Collaborators
Midwest Center for Metabolic and Cardiovascular Research
National Cattlemen's Beef Association

Layout table for additonal information
Responsible Party: Midwest Center for Metabolic and Cardiovascular Research
ClinicalTrials.gov Identifier: NCT03202680     History of Changes
Other Study ID Numbers: MB-1606
First Posted: June 28, 2017    Key Record Dates
Last Update Posted: July 24, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Insulin Resistance
Prediabetic State
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Diabetes Mellitus
Endocrine System Diseases
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs